PT-141: A Central Desire Signal, One Approved Indication

The short version

PT-141, known in its pharmaceutical form as bremelanotide, is a synthetic cyclic heptapeptide that activates melanocortin receptors in the brain — specifically MC4R and MC3R, concentrated in the hypothalamus and limbic system. Unlike any vascular drug, it works centrally, on the neural circuitry of sexual motivation rather than on blood-vessel physiology.

It was studied across two large Phase 3 randomized controlled trials in premenopausal women diagnosed with acquired, generalized hypoactive sexual desire disorder (HSDD). Both trials found statistically significant improvements in sexual desire and desire-related distress compared with placebo ^[10]. The FDA approved bremelanotide injection in June 2019 for this specific indication only — premenopausal women with HSDD — under NDA 210557 ^[12].

Several hard limits belong alongside that approval:

• PT-141 is not approved for men, postmenopausal women, or sexual performance enhancement in anyone.
• The Phase 3 effect sizes, while statistically significant, are modest, and independent re-analyses have questioned clinical meaningfulness [controversies].
• Nausea affects approximately 40% of patients over long-term use ^[11].
• The drug label carries a warning on transient blood-pressure increases and contraindicates use in uncontrolled hypertension or cardiovascular disease ^[12].
• Material sold as "PT-141 research chemical" exists outside the pharmaceutical approval framework; its identity, purity and concentration are unverified.

This page summarizes the research; it is not advice and lists no human dose.

What it is

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide lactam with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, where the lactam bridge links the Asp and Lys side chains. It is a structural analogue of alpha-melanocyte-stimulating hormone (alpha-MSH) and is closely related to — but distinct from — melanotan II: PT-141 replaces the C-terminal amide of melanotan II with a carboxylic acid, and it was developed specifically for central activity with reduced melanogenic (tanning) effect.

The IUPAC name is bremelanotide; "PT-141" is the development code that persists in research-chemical communities. Pharmaceutical bremelanotide (the approved medicine) is a 1.75 mg subcutaneous autoinjector. Material sold as "PT-141" by research chemical suppliers is not the approved pharmaceutical and has not been evaluated for human use under regulated conditions.

How it works

PT-141 activates melanocortin 4 receptor (MC4R) and melanocortin 3 receptor (MC3R). These receptors are expressed in hypothalamic nuclei — including the medial preoptic area — and in the limbic system, which is the brain's emotional and motivational processing center.

The leading mechanistic hypothesis is that MC4R stimulation in those hypothalamic circuits engages dopaminergic pathways governing sexual desire. A 2022 fMRI crossover study in 31 premenopausal women with HSDD mapped this directly: MC4R agonism significantly increased sexual desire for up to 24 hours and produced measurable changes in brain activity in response to erotic stimuli — enhanced functional connectivity between the amygdala and insula, and increased cerebellar and supplementary-motor area activation ^[9]. This is neuroimaging-level evidence for a central mechanism.

What PT-141 does not do is important to understand. It does not act through the hypothalamic-pituitary-gonadal axis and does not directly raise testosterone, LH or FSH. It does not act as a PDE-5 inhibitor and does not dilate blood vessels to facilitate erection. It operates on the neurological experience of desire, not on the downstream physiology.

A 2025 hamster study adds nuance: MC3R/MC4R mRNA in the ventral tegmental area was documented, but bremelanotide at tested doses did not enhance the rewarding aspect of sexual interaction (conditioned place preference), suggesting the dopamine-reward circuit is more complex than a simple MC4R-on switch ^[8].

What the research shows

Phase 3 efficacy. The RECONNECT trials — two identical Phase 3 RCTs (combined n=1267 premenopausal women with HSDD) — found bremelanotide 1.75 mg subcutaneous as-needed produced statistically significant improvement in sexual desire (integrated FSFI-desire score +0.35, P < 0.001) and reduced desire-related distress (integrated FSDS-DAO item 13 score −0.33, P < 0.001) versus placebo over 24 weeks. Both coprimary endpoints were met in both trials ^[10]. The most common adverse events were nausea, flushing and headache.

Long-term safety extension. In the 52-week open-label extension of RECONNECT (684 women enrolled), no new safety signals emerged and sexual desire improvements were sustained. The most common drug-related treatment-emergent adverse events were nausea (40.4%), flushing (20.6%) and headache (12.0%) ^[11]. Nausea was the principal tolerability issue and a notable driver of discontinuation.

Neuroimaging mechanism. The 2022 fMRI study of 31 premenopausal women with HSDD provided mechanistic confirmation: MC4R agonism increased sexual desire for up to 24 hours and produced altered brain processing of erotic stimuli (amygdala-insula connectivity, cerebellar/supplementary-motor activation) ^[9], making this one of the more directly mechanistically evidenced approvals in sexual medicine.

Regulatory label. The FDA prescribing information (NDA 210557, approved June 21, 2019) specifies: approved indication is acquired, generalized HSDD in premenopausal women; approved dose is 1.75 mg subcutaneously as-needed (maximum one dose per 24 hours, no more than 8 doses per month); terminal half-life approximately 2.7 hours (range 1.9–4.0 hours); volume of distribution 25.0 L; clearance 6.5 L/h; renal/fecal excretion 64.8% / 22.8%; and a warning on transient blood-pressure increase with contraindication in uncontrolled hypertension or cardiovascular disease ^[12].

Reported effects, cautions and safety

Key regulatory and clinical cautions

• Approved only for premenopausal women with HSDD. PT-141/bremelanotide is not approved for men, postmenopausal women, or use to enhance sexual performance in people without an HSDD diagnosis ^[12].
• Modest effect sizes, disputed clinical meaningfulness. Independent re-analyses have argued that the statistically significant improvements in desire and distress are small in absolute magnitude, and the clinical meaningfulness of the FSFI-desire and FSDS-DAO outcome measures has been questioned [controversies noted in research].
• Nausea affects ~40% over long-term use. In the 52-week extension, nausea was the most common drug-related adverse event (40.4%), with flushing (20.6%) and headache (12.0%) also frequent ^[11]. Injection timing strategies to mitigate nausea exist but are management strategies, not solutions.
• Transient blood-pressure increase. The label documents a transient systolic/diastolic increase and contraindicates use in uncontrolled hypertension or known cardiovascular disease ^[12].
• Hyperpigmentation with frequent dosing. Repeated frequent dosing has produced hyperpigmentation of the face, gums and breasts, attributed to MC1R activation; documented in the original development program.
• PT-141 research chemical is not the approved pharmaceutical. Material sold outside the approved supply chain has no regulatory oversight of identity, purity, or concentration.
• MC4R and appetite. MC4R is also expressed in appetite circuits; weight and caloric-intake effects observed at high-frequency Phase 1 dosing are a relevant pharmacological consideration, not an approved use.
• Does not raise testosterone or act via the HPG axis. A common misconception; PT-141 does not stimulate LH/FSH or directly raise sex hormone levels. It is not a PDE-5 inhibitor ^[12].
• Off-label use in men. Phase 2 erectile dysfunction data exist but no Phase 3 program for men was completed; the approval does not extend to men.

Where it fits in reproductive research

PT-141 is the sole member of this desk with a regulatory approval, and that approval is narrow: premenopausal women with acquired, generalized HSDD. That narrowness is part of the scientific record, not a limitation to be glossed. The mechanism — central MC4R agonism modulating desire circuitry — is well-characterized and distinguishes it clearly from every vascular approach to sexual dysfunction.

Compared with kisspeptin, which works through the upstream reproductive hormone axis and has no approved form at all, PT-141 sits downstream at the level of the brain's desire processing, and it has the most human efficacy data of any compound on this desk. The two peptides answer different questions: kisspeptin asks whether the hormonal axis can be restarted; PT-141 asks whether the experience of desire can be centrally amplified. See the comparison page for the full side-by-side.